Adcirca FDA Approval History
FDA Approved: Yes (First approved May 22, 2009)
Brand name: Adcirca
Generic name: tadalafil
Dosage form: Tablets
Company: United Therapeutics Corporation
Treatment for: Pulmonary Arterial Hypertension
Adcirca (tadalafil) is a once-daily phosphodiesterase type 5 (PDE5) inhibitor for the treatment of pulmonary arterial hypertension (PAH).
Development timeline for Adcirca
| Date | Article |
|---|---|
| May 26, 2009 | Approval FDA Approves Adcirca (tadalafil) Tablets for the Treatment of Pulmonary Arterial Hypertension |
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
